Efficacy and safety of edoxaban for treatment of portal vein thrombosis following danaparoid sodium in patients with liver cirrhosis

• DOI: 10.1111/hepr.12895
• Publication Date: 2017-03-25T09:06:32Z
• Authors: Yuko Nagaoki; Hiroshi Aikata; Kana Daijyo; Yuji Teraoka; Fumi Shinohara; Yuki Nakamura; Masahiro Hatooka; Kei Morio; Takashi Nakahara; Tomokazu Kawaoka; Masataka Tsuge; Akira Hiramatsu; Michio Imamura; Yoshiiku Kawakami; Hidenori Ochi; Kazuaki Chayama
• Keywords: Edoxaban; Warfarin Sodium

To compare the efficacy and safety of edoxaban warfarin for treatment portal vein thrombosis (PVT) following danaparoid sodium in patients with liver cirrhosis.Fifty cirrhotic PVT treated initially 2 weeks were enrolled this retrospective cohort study. Treatment was later switched to either (n = 20) or 30). We compared up 6 months. The volume measured by dynamic computed tomography before treatment, at weeks, 1, 3, months.There no significant differences clinical characteristics two groups. reduced from 1.42 cm3 0.42 months, prevented exacerbation months after (P 0.016). In contrast, resulted increased 1.73 2.85 despite control international normalized ratio 57% 0.005). Multivariate regression analysis identified therapy as single independent determinant reduction 0.0014, hazard 6.400). Clinically gastrointestinal bleeding encountered 3 20 (15%) group 30 (7%) 0.335).Edoxaban is an effective anticoagulant could be potentially considered one options patients.